Skip to main navigation Skip to search Skip to main content

Phase I and pharmacokinetic study of everolimus and capecitabine in patients with solid tumors

  • J. Wilmink
  • , M.J. Deenen
  • , H. Klümpen
  • , R. Sparidans
  • , J. Beijnen
  • , J.H. Schellens
  • , D. Richel

    Research output: Contribution to journal › Meeting Abstract › Academic

    Abstract

    Background: Results form (pre)clinical studies suggest that mTOR inhibitors are promising drugs for the treatment of various types of cancer. Everolimus seems the most attractive mTOR inhibitor because of the favorable pharmacokinetic profile and possibility of oral administration. Based on preclinical findings, mTOR inhibitors may be more efficacious when used in combination with cytostatic drugs. Methods: Patients (pts) with solid tumors were studied to determine the maximum tolerated dose (MTD), safety and pharmacokinetics (PK) of a fixed dose everolimus, 5 mg BID continuously and capecitabine (cap) BID for 14 days in 3-weekly intervals. The dose of cap was escalated in 4 dose levels (1-4): 500, 650, 800, and 1000 mg/m2. 3 pts per dose level were treated, and increased to 6 in case of occurrence of dose-limiting toxicity (DLT). The MTD was defined as the level below the highest level at which ≥2 out of 6 pts develop DLT. The PK of cap and its metabolites were assessed on 2 days: without, and with everolimus on steady state. Vice versa, the PK for everolimus was assessed over a 12h interval at steady state with, and without cap. Trough concentrations for everolimus were sampled in the first 4 weeks of treatment. Results: 17 pts: 9 pancreatic, 4 gastrointestinal and 4 others, were recruited. 4, 5, 3, and 5 pts were treated at dose level 1, 2, 3, and 4, respectively. DLT occurred in 2 patients. The MTD was dose-level 3 (800 mg/m2). Most frequently occurring toxicities were fatigue (53%), stomatitis (41%), hand-foot syndrome (29%), nausea (24%), and diarrhea (18%). 2 pts had a partial response, 5 had stable disease and 10 had PD. Steady state for everolimus was reached in 7 days. Mean treatment duration with everolimus was 126 days (range 12-329). There was no significant PK interaction: intrapatient variability in the area under the curve of everolimus (AUCeverolimus) (± cap) was 1.7%; interpatient variability AUCeverolimus was 35% (CV). Intrapatient variability of cap (± everolimus) was 8.3%; interpatient variability of AUCcap was 50% (CV). Similarly, there was no PK interaction for metabolites of cap. Conclusions: Everolimus 5 mg twice daily continuously can be safely added to capecitabine 800 mg/m2 BID and shows promising activity.
    Original languageEnglish
    JournalJournal of Clinical Oncology
    Volume28
    Issue number15
    Publication statusPublished - 20 May 2010

    UN SDGs

    This output contributes to the following UN Sustainable Development Goals (SDGs)

    1. SDG 3 - Good Health and Well-being
      SDG 3 Good Health and Well-being

    Keywords

    • everolimus
    • capecitabine
    • mammalian target of rapamycin inhibitor
    • cytostatic agent
    • solid malignant neoplasm
    • patient
    • pharmacokinetics
    • oncology
    • society
    • steady state
    • toxicity
    • metabolite
    • nausea
    • diarrhea
    • treatment duration
    • area under the curve
    • clinical study
    • neoplasm
    • oral drug administration
    • maximum tolerated dose
    • safety
    • fatigue
    • stomatitis
    • hand foot syndrome

    Fingerprint

    Dive into the research topics of 'Phase I and pharmacokinetic study of everolimus and capecitabine in patients with solid tumors'. Together they form a unique fingerprint.

    Cite this